The first trial of adjuvant platinum-based chemotherapy plus paclitaxel in patients with high-risk penile cancer provided some insights.

CHICAGO -- A neoadjuvant chemotherapy regimen of cisplatin (Platinol), nab-paclitaxel (Abraxane), capecitabine (Xeloda), and ...

The addition of low-intensity electric tumor treating fields (TTFields) therapy to first-line standard chemotherapy was ...

BioLineRx Ltd’s (NASDAQ:BLRX) poster, which includes new data from the single-arm pilot phase of the investigator-initiated, ...

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...

Here is a recap of every FDA approval announced by the regulatory agency in the month of May, spanning various cancer types.

Amplia Therapeutics is making strides with its candidate that works on the anti-fibrotic path to tackling pancreatic cancer.

Metastatic breast cancer market is projected to grow significantly through 2035, driven by rising cases, treatment advances, and expanding R&D investments.

HemoSonics, LLC, a medical device company focused on acute bleeding management, today announced the company has won the Triangle Business Journal 2025 Life Sciences Award in the Best Medical Device ...

1 “Globally, penile cancer is rare. However ... higher GI toxicities and hematological toxicities with the 5-FU arm, more neuropathy and liver dysfunction with paclitaxel, similar results in EORTC and ...

Bio-Path expects to utilize an advisory panel of AML experts to assist in the design of the final clinical development plans through potential FDA approval. Other significant milestones expected ...